.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 4,107,315

« Back to Dashboard

Details for Patent: 4,107,315

Title: 5-(Pyridinyl)-2(1H)-pyridinones
Abstract:Compounds useful as cardiotonic agents are 1-R-3-Q-5-PY-2(1H)-pyridinones (I) where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, Q is amino (preferred), lower-alkylamino, di-(lower-alkyl)amino or NHAc, Ac is lower-alkanoyl or lower-carbalkoxy, and PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents. The corresponding compounds where Q is nitro, carbamyl, cyano, halo or hydrogen are useful as intermediates and those where Q is hydrogen or cyano also are useful as cardiotonic agents. Said compounds are prepared: by reacting .alpha.-PY-.beta.-(R.sub.1 R.sub.2 N)acrolein (II) with malonamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinamide (Ia) and reacting Ia with a reagent capable of converting carbamyl to amino to produce 3-amino-5-PY-2(1H)-pyridinone (Ib); by reacting II or .alpha.-PY-malonaldehyde (II') with .alpha.-cyanoacetamide to produce 1,2-dihydro-2-oxo-5-PY-nicotinonitrile (III) and partially hydrolyzing III to produce Ia; and, by heating 1,2-dihydro-2-oxo-5-PY-nicotinic acid (IV) with a mixture of concentrated sulfuric acid and concentrated nitric acid to produce 3-nitro-5-PY-2(1H)-pyridinone (Ic) and then either reducing Ic to produce Ib or first reacting Ic with an alkylating agent to produce 1-R'-3-nitro-5-PY-2(1H)-pyridinone (Id) and reducing Id to produce 1-R'-3-amino-5-PY-2(1H)-pyridinone (Ib) where R' is lower-alkyl or lower-hydroxyalkyl. Other derivatives of I where Q is amino are shown.
Inventor(s): Lesher; George Y. (Schodack, NY), Opalka, Jr.; Chester J. (Schodack, NY)
Assignee: Sterling Drug Inc. (New York, NY)
Filing Date:Jul 25, 1977
Application Number:05/818,724
Claims:1. A 1-R-3-Q-5-PY-2(1H)-pyridinone having the formula: ##STR4## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower hydroxy alkyl and Q is hydrogen or halo or a pharmaceutically-acceptable acid-addition salt thereof.

2. A compound according to claim 1 where R and Q are each hydrogen.

3. A compound according to claim 1 where Q is halo and R is hydrogen.

4. 5-(4-Pyridinyl)-2(1H)-pyridinone according to claim 2.

5. 3-Chloro-5-(4-pyridinyl)-2(1H)-pyridinone according to claim 3.

6. 3-Bromo-5-(4-pyridinyl)-2(1H)-pyridinone according to claim 3.

7. A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic 1-R-3-Q-5-PY-2(1H)-pyridinone having the formula ##STR5## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is hydrogen, or pharmaceutically-acceptable acid-addition salt thereof.

8. A composition according to claim 7 where the active component is 5-(4-pyridinyl)-2(1H)-pyridinone.

9. The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic 1-R-3-Q-5-PY-2(1H)-pyridone having the formula ##STR6## where PY is 4- or 3- or 2-pyridinyl or 4- or 3- or 2-pyridinyl having one or two lower-alkyl substituents, R is hydrogen, lower-alkyl or lower-hydroxyalkyl and Q is hydrogen, or pharmaceutically-acceptable acid-addition salt thereof.

10. The method according to claim 9 where the 1-R-3-Q-5-PY-2(1H)-pyridinone is 5-(4-pyridinyl)-2(1H)-pyridinone.

11. The process of preparing the compound of claim 1 where Q is halo and R is hydrogen which comprises reacting 5-PY-2(1H)-pyridinone with halogen to produce 3-halo-5-PY-2(1H)-pyridinone where PY is defined as in claim 1.

12. The process for preparing the compounds of claim 1 where Q is hydrogen which comprises reacting the corresponding compound where Q is carboxy or cyano with aqueous mineral acid.

13. The process according to claim 12 which comprises reacting 1,2-dihydro-2-oxo-5-(4-pyridinyl)-nicotinonitrile or 1,2-dihydro-2-oxo-5-(4-pyridinyl)-nicotinic acid with aqueous sulfuric acid to produce 5-(4-pyridinyl)-2(1H)-pyridinone.

14. The process for preparing the compound of claim 1 where Q is halo which comprises the steps of heating 1,2-dihydro-2-oxo-5-PY-nicotinonitrile or 1,2-dihydro-2-oxo-5-PY-nicotinic acid with an aqueous mineral acid to produce 5-PY-2(1H)-pyridinone and reacting 5-PY-2(1H)-pyridinone with halogen to produce the corresponding 3-halo-5-PY-2(1H)-pyridinone.

15. The process which comprises the steps of reacting 1-R-5-PY-2(1H)-pyridinone with halogen to produce the corresponding 1-R-3-halo-5-PY-2(1H)-pyridinone according to claim 1 and reacting said 3-halo compound with a lower-alkylamine or di-(lower-alkyl)amine, to produce the corresponding respective 3-(lower-alkylamino) or 3-[di-(lower-alkyl)amino] compound, where PY and R have the meanings given in claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc